Literature DB >> 19906835

Short form 1b human prolactin receptor down-regulates expression of the long form.

Dunyong Tan1, Ameae M Walker.   

Abstract

Alternative splicing produces different human prolactin (PRL) receptors. These include a long form (LF) and two short forms (SF1a and SF1b). The SFs of the receptor can act as dominant negatives for PRL effector function through the LF. This is proposed to be due to LF-SF heterodimerization and resultant interference with LF-LF dimer signaling. We, along with others, have provided evidence for LF-SF heterodimerization of the human receptors in support of this mechanism, along with others. However, to further investigate the ways SF may influence LF function, we co-transfected human embryonic kidney 293 cells with vectors coding for tagged (green fluorescent protein (GFP) or luciferase) LF alone or plus untagged SF1b and measured LF-GFP intensity, LF-luciferase activity, and LF mRNA 48 h later. Equal amounts of SF1b cDNA decreased LF-GFP fluorescence intensity, LF-luciferase activity, and LF mRNA by 80-100%. Similar co-transfections with untagged LF had no significant effect on tagged LF expression. Use of hygromycin showed degradation of already formed protein was the same for LF-luciferase alone and LF-luciferase with SF1b. Inhibition of mRNA synthesis, on the other hand, showed that SF1b expression accelerated LF mRNA degradation two- to three-fold. SF1b also down-regulated expression of endogenous LF mRNA in T47D breast cancer cells and opposed an increase in cell number resulting from transfection with extra LF alone. These results demonstrate a previously unrecognized mechanism whereby SF1b affects the end result of signaling through the LF receptor. The effects on cell number also support the concept that the LF:SF1b ratio may be relevant to tumor growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906835     DOI: 10.1677/JME-09-0101

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  8 in total

Review 1.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

2.  Multiple cell types in the oviduct express the prolactin receptor.

Authors:  Kelly C Radecki; Matthew J Ford; Hollian R Phillipps; Mary Y Lorenson; David R Grattan; Yojiro Yamanaka; Ameae M Walker
Journal:  FASEB Bioadv       Date:  2022-04-15

3.  Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.

Authors:  Erika Ginsburg; Stefanie Alexander; Sarah Lieber; Sarah Tarplin; Luwanda Jenkins; Linda Pang; Christopher D Heger; Paul Goldsmith; Barbara K Vonderhaar
Journal:  BMC Cancer       Date:  2010-12-13       Impact factor: 4.430

4.  The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synthesis through the NEK9-Hippo axis in pancreatic cancer.

Authors:  Huizhen Nie; Pei-Qi Huang; Shu-Heng Jiang; Qin Yang; Li-Peng Hu; Xiao-Mei Yang; Jun Li; Ya-Hui Wang; Qing Li; Yi-Fan Zhang; Lei Zhu; Yan-Li Zhang; Yanqiu Yu; Gary Guishan Xiao; Yong-Wei Sun; Jianguang Ji; Zhi-Gang Zhang
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

5.  Splice modulating oligomers as cancer therapeutics.

Authors:  KuanHui E Chen; Ameae M Walker
Journal:  Genes Cancer       Date:  2022-08-26

Review 6.  Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.

Authors:  Raghuveer Kavarthapu; Maria L Dufau
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-15       Impact factor: 6.055

7.  Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer.

Authors:  Louise Maymann Nitze; Elisabeth Douglas Galsgaard; Nanni Din; Vibe Luja Lund; Birgitte Bruun Rasmussen; Martin Werner Berchtold; Leif Christensen; Svetlana Panina
Journal:  Breast Cancer Res Treat       Date:  2013-10-22       Impact factor: 4.872

8.  Mechanisms of JAK/STAT pathway negative regulation by the short coreceptor Eye Transformer/Latran.

Authors:  Katherine H Fisher; Wojciech Stec; Stephen Brown; Martin P Zeidler
Journal:  Mol Biol Cell       Date:  2015-12-10       Impact factor: 4.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.